Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
INAVA pseudogene 1 (INAVAP1) is classified as a pseudogene, meaning it is a DNA sequence similar to the protein-coding gene INAVA but does not code for a functional protein[7][9]. Pseudogenes may arise from duplication or retrotransposition events, often acquiring mutations that prevent expression or protein production[4]. There is no evidence that INAVAP1 is expressed as a protein or RNA with biological activity, nor is it associated with any specific diseases or relevant as a druggable target. Its only relevance is as a sequence-related entity to the functional gene INAVA, which is involved in immune signaling and diseases like inflammatory bowel disease; however, these functions are not attributed to the pseudogene[3][5][7][9]. Key clarification: INAVAP1 should not be listed as a therapeutic target, as it is a noncoding pseudogene without evidence for biological, clinical, or pharmacological relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on INAVA pseudogene 1 (INAVAP1).